Research ArticleOriginal Research

Novel Models to Identify Census Tracts for Hepatitis C Screening Interventions

Thomas Ludden, Lindsay Shade, Jeremy Thomas, Brisa Urquieta de Hernandez, Sveta Mohanan, Mark W. Russo, Michael Leonard, Philippe J. Zamor, Charity G. Patterson and Hazel Tapp
The Journal of the American Board of Family Medicine May 2020, 33 (3) 407-416; DOI: https://doi.org/10.3122/jabfm.2020.03.190305

References

  1. 1.↵
    1. Edlin BR,
    2. Eckhardt BJ,
    3. Shu MA,
    4. Holmberg SD,
    5. Swan T
    . Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology 2015;62:1353–63.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Hofmeister MG,
    2. Rosenthal EM,
    3. Barker LK,
    4. et al
    . Estimating prevalence of hepatitis C virus infection in the United States, 2013–2016. Hepatology 2018;69:1020–31.
    OpenUrl
  3. 3.↵
    CDC. Hepatitis C questions and answers for health professionals. Available from: https://www.cdc.gov/hepatitis/hcv/hcvfaq.htm. Accessed January 17, 2019.
  4. 4.↵
    1. Smith BD,
    2. Morgan RL,
    3. Beckett GA,
    4. et al
    . Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR Recomm Rep 2012;61:1–32.
    OpenUrlPubMed
  5. 5.↵
    1. Armstrong GL,
    2. Wasley A,
    3. Simard EP,
    4. McQuillan GM,
    5. Kuhnert WL,
    6. Alter MJ
    . The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705–14.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Rein DB,
    2. Wittenborn JS,
    3. Weinbaum CM,
    4. Sabin M,
    5. Smith BD,
    6. Lesesne SB
    . Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig Liver Dis 2011;43:66–72.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Wenger PJ,
    2. Rottnek F,
    3. Parker T,
    4. Crippin JS
    . Assessment of hepatitis C risk factors and infection prevalence in a jail population. Am J Public Health 2014;104:1722–7.
    OpenUrl
  8. 8.↵
    1. Ha S,
    2. Totten S,
    3. Pogany L,
    4. Wu J,
    5. Gale-Rowe M
    . Hepatitis C in Canada and the importance of risk-based screening. Can Commun Dis Rep 2016;42:57–62.
    OpenUrl
  9. 9.↵
    1. Akiyama MJ,
    2. Kaba F,
    3. Rosner Z,
    4. et al
    . Correlates of hepatitis C virus infection in the targeted testing program of the New York City jail system: epidemiologic patterns and priorities for action. Public Health Rep 2017;132:41–7.
    OpenUrl
  10. 10.↵
    1. Barth H
    . Hepatitis C virus: is it time to say goodbye yet? Perspectives and challenges for the next decade. World J Hepatol 2015;7:725–37.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. El-Serag HB,
    2. Kanwal F,
    3. Richardson P,
    4. Kramer J
    . Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology 2016;64:130–7.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Kanwal F,
    2. Kramer J,
    3. Asch SM,
    4. Chayanupatkul M,
    5. Cao Y,
    6. El-Serag HB
    . Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology 2017;153:996–1005.e1.
    OpenUrlCrossRef
  13. 13.↵
    1. Backus LI,
    2. Belperio PS,
    3. Shahoumian TA,
    4. Mole LA
    . Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease. Hepatology 2019;69:487–97.
    OpenUrl
  14. 14.↵
    1. Tada T,
    2. Kumada T,
    3. Toyoda H,
    4. et al
    . Viral eradication reduces all-cause mortality, including non-liver-related disease, in patients with progressive hepatitis C virus-related fibrosis. J Gastroenterol Hepatol 2017;32:687–94.
    OpenUrl
  15. 15.↵
    CDC. Viral hepatitis surveillance—United States, 2016. Available from: https://www.cdc.gov/hepatitis/statistics/2016surveillance/index.htm. Accessed January 17, 2019.
  16. 16.↵
    1. Kallman JB,
    2. Arsalla A,
    3. Park V,
    4. et al
    . Screening for hepatitis B, C and non-alcoholic fatty liver disease: a survey of community-based physicians. Aliment Pharmacol Ther 2009;29:1019–24.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    1. Ludden TM,
    2. Taylor YJ,
    3. Simmons LK,
    4. et al
    . Using community-based participatory research to develop geospatial models toward improving community health for disadvantaged hispanic populations in Charlotte, NC. J Primary Prevent 2018;39:171–90.
    OpenUrl
  18. 18.↵
    1. Friedman EE,
    2. Dean HD,
    3. Duffus WA
    . Incorporation of social determinants of health in the peer-reviewed literature: a systematic review of articles authored by the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Public Health Rep 2018;133:392–412.
    OpenUrl
  19. 19.↵
    1. Daniel H,
    2. Bornstein SS,
    3. Kane GC
    ; Health and Public Policy Committee of the American College of Physicians. Addressing social determinants to improve patient care and promote health equity: an American College of Physicians position paper. Ann Intern Med 2018;168:577–8.
    OpenUrl
  20. 20.↵
    1. Dulin MF,
    2. Tapp H,
    3. Smith HA,
    4. et al
    . A trans-disciplinary approach to the evaluation of social determinants of health in a Hispanic population. BMC Public Health 2012;12:769.
    OpenUrlPubMed
  21. 21.↵
    1. Bazemore A,
    2. Phillips RL,
    3. Miyoshi T
    . Harnessing Geographic Information Systems (GIS) to enable community-oriented primary care. J Am Board Fam Med 2010;23:22–31.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Dulin MF,
    2. Ludden TM,
    3. Tapp H,
    4. et al
    . Using Geographic Information Systems (GIS) to understand a community's primary care needs. J Am Board Fam Med 2010;23:13–21.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Dulin MF,
    2. Ludden TM,
    3. Tapp H,
    4. et al
    . Geographic Information Systems (GIS) demonstrating primary care needs for a transitioning hispanic community. J Am Board Fam Med 2010;23:109–20.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Ford MM,
    2. Desai PS,
    3. Maduro G,
    4. Laraque F
    . Neighborhood inequalities in hepatitis C mortality: spatial and temporal patterns and associated factors. J Urban Health 2017;94:746–55.
    OpenUrl
  25. 25.↵
    1. Edlin BR,
    2. Winkelstein ER
    . Can hepatitis C be eradicated in the United States? Antiviral Res 2014;110:79–93.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Dean HD,
    2. Fenton KA
    . Addressing social determinants of health in the prevention and control of HIV/AIDS, viral hepatitis, sexually transmitted infections, and tuberculosis. Public Health Rep 2010;125:1–5.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Tohme RA,
    2. Xing J,
    3. Liao Y,
    4. Holmberg SD
    . Hepatitis C testing, infection, and linkage to care among racial and ethnic minorities in the United States, 2009–2010. Am J Public Health 2013;103:112–9.
    OpenUrlCrossRefPubMed
  28. 28.↵
    Atrium Health. Mapping social determinants of health. Available from: http://tinyurl.com/SDH-Story-Map. Accessed May 12, 2018.
  29. 29.↵
    1. Tapp H,
    2. Kuhn L,
    3. Alkhazraji T,
    4. et al
    . Adapting community based participatory research (CBPR) methods to the implementation of an asthma shared decision making intervention in ambulatory practices. J Asthma 2014;51:380–90.
    OpenUrlPubMed
  30. 30.↵
    1. Tapp H,
    2. Smith HA,
    3. Dixon JT,
    4. Ludden T,
    5. Dulin M
    . Evaluating primary care delivery systems for an uninsured Hispanic immigrant population. Fam Community Health 2013;36:19–33.
    OpenUrlPubMed
  31. 31.↵
    1. Cooke GS,
    2. Hallett TB
    . HCV and HIV: shared challenges, shared solutions. Lancet Infect Dis 2016;16:755–6.
    OpenUrl
  32. 32.↵
    1. Martin NK,
    2. Hickman M,
    3. Hutchinson SJ,
    4. Goldberg DJ,
    5. Vickerman P
    . Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis 2013;57:S39–S45.
    OpenUrlCrossRefPubMed
  33. 33.↵
    National Academies of Sciences, Committee on a National Strategy for the Elimination of Hepatitis B and C, Board on Population Health and Public Health Practice. A national strategy for the elimination of hepatitis B and C: phase two report. Washington, D.C.: National Academies Press; 2017.
  34. 34.↵
    1. Moyer VA
    , US Preventative Services Task Force. Screening for hepatitis C virus infection in adults. Ann Intern Med 2013;159:349–57.
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.↵
    1. Chou RC,
    2. Cottrell EB,
    3. Wasson N,
    4. Rahman B,
    5. Guise JM
    . Screening for hepatitis C virus infection in adults. Ann Intern Med 2013;158:101–8.
    OpenUrlCrossRefPubMedWeb of Science
  36. 36.↵
    1. Joshi SN
    . Hepatitis C screening. Ochsner J 2014;14:664–8.
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    1. Smith BD,
    2. Yartel AK
    . Comparison of hepatitis C virus testing strategies: birth cohort versus elevated alanine aminotransferase levels. Am J Prev Med 2014;47:233–41.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Southern WN,
    2. Norton B,
    3. Steinman M,
    4. et al
    . A birth-cohort testing intervention identified hepatitis c virus infection among patients with few identified risks: a cross-sectional study. BMC Infect Dis 2015;15:553.
    OpenUrl
  39. 39.↵
    1. Klevens RM,
    2. Hu DJ,
    3. Jiles R,
    4. Holmberg SD
    . Evolving epidemiology of hepatitis C virus in the United States. Clin Infect Dis 2012;55:S3–9.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Noble D,
    2. Smith D,
    3. Mathur R,
    4. Robson J,
    5. Greenhalgh T
    . Feasibility study of geospatial mapping of chronic disease risk to inform public health commissioning. BMJ Open 2012;2:e000711.
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    1. Iliopoulou P,
    2. Tsatsaris A,
    3. Katsios I,
    4. et al
    . Risk mapping of visceral leishmaniasis: a spatial regression model for Attica Region, Greece. Trop Med Infect Dis 2018;3:83.
    OpenUrl
  42. 42.↵
    1. Sharif-Askary B,
    2. Bittar PG,
    3. Farjat A,
    4. Liu B,
    5. Vissoci J,
    6. Allori AC
    . Geospatial econometric exploration of risk factors for loss to followup in cleft care. Plast Reconstr Surg Glob Open 2018;6:1–2.
    OpenUrl
  43. 43.↵
    1. Lal A
    . Spatial modelling tools to integrate public health and environmental science, illustrated with infectious cryptosporidiosis. Int J Environ Res Public Health 2016;13:186.
    OpenUrl
  44. 44.↵
    1. Stopka TJ,
    2. Goulart MA,
    3. Meyers DJ,
    4. et al
    . Identifying and characterizing hepatitis C virus hotspots in Massachusetts: a spatial epidemiological approach. BMC Infect Dis 2017;17:294.
    OpenUrl
  45. 45.↵
    1. Kauhl B,
    2. Heil J,
    3. Hoebe CJ,
    4. Schweikart J,
    5. Krafft T,
    6. Dukers-Muijrers NH
    . The spatial distribution of hepatitis C virus infections and associated determinants–an application of a geographically weighted Poisson regression for evidence-based screening interventions in hotspots. PLoS One 2015;10:e0135656.
    OpenUrl
  46. 46.↵
    1. Heil J,
    2. Hoebe C,
    3. Cals JWL,
    4. Ter Waarbeek HLG,
    5. van Loo IHM,
    6. Dukers-Muijrers N
    . Detecting hepatitis B and C by combined public health and primary care birth cohort testing. Ann Fam Med 2018;16:21–27.
    OpenUrlAbstract/FREE Full Text
  47. 47.↵
    U.S. Preventive Services Task Force. Draft recommendation statement: hepatitis C virus infection in adolescents and adults: screening. Available from: https://www.uspreventiveservicestaskforce.org/Page/Document/draft-recommendation-statement/hepatitis-c-screening1. Accessed December 23, 2019.
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Keywords